Ghent University Academic Bibliography

Advanced

Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease

R Selvam, P Maheswari, P Kavitha, M Ravichandran, Benedikt Sas UGent and CN Ramchand (2009) INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC. 46(1). p.79-85
abstract
The pathophysiology of inflammatory bowel disease (IBD) involves the production of diverse lipid mediators, namely eicosanoid, lysophospholipids, and platelet-activating factor, in which phospholipase A(2) (PLA(2)) is the key enzyme. Thus, it has been postulated that control of lipid mediators production by inhibition of PLA(2) would be useful for the treatment of IBD. This hypothesis has been tested in the present study by examining the therapeutic effect of a novel natural probitic Bacillus subtilis PB6 (ATCC- PTA 6737). B. subtilis PB6 is found to secrete surfactins (cyclin lipopeptides) which have anti-bacterial potential. These surfactins inhibit PLA(2), a rate-limiting enzyme involved in the arachidonic acid associated inflammatory pathway and could downregulate the inflammatory response by regulating the eicosanoid and cytokine pathways. With this concept, an experimental animal trial has been conducted in a rat model of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The oral administration of PB6 suppresses the colitis as measured by mortality rate, changes in the weight gain, colon morphology and the levels of plasma cytokines. The animals treated orally with PB6 at 1.5 x 10(8) CFU/kg thrice daily from day 4 to 10 significantly improve gross pathology of the colon and regain the colon weight to normal (p<0.05), compared to TNBS-induced positive control. The plasma levels of pro-inflammatory cytokines (TNR-alpha, IL-1 beta, IL-6 and IFN-gamma) are also significantly lowered (p<0.05) and anti-inflammatory cytokine (IL-10 and TGF-beta) significantly (p<0.05) increased after the oral administration of PB6 on day 11. The present study supports the concept that PB6 inhibits PLA(2) by the secreting surfactins. In a clinical investigation it is found to be well tolerated by all the healthy volunteers.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Bacillus subtilis PB6, Inflammatory bowel disease, TNBS-induced colitis, Wistar rats, Cytokines, ACTIVATED PROTEIN-KINASE, TUMOR-NECROSIS-FACTOR, LACTIC-ACID BACTERIA, INDUCED COLITIS, LACTOBACILLUS STRAINS, CELLS, MURINE, MICE, INHIBITOR, MODEL
journal title
INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC
Indian J. Biochem. Biophys.
volume
46
issue
1
issue title
Free radicals and antioxidants in human health
pages
79 - 85
Web of Science type
Article
Web of Science id
000264812400012
JCR category
BIOPHYSICS
JCR impact factor
0.574 (2009)
JCR rank
68/74 (2009)
JCR quartile
4 (2009)
ISSN
0301-1208
language
English
UGent publication?
no
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
627192
handle
http://hdl.handle.net/1854/LU-627192
alternative location
http://nopr.niscair.res.in/bitstream/123456789/3339/1/IJBB%2046(1)%2079-85.pdf
date created
2009-05-14 10:05:36
date last changed
2016-12-19 15:40:12
@article{627192,
  abstract     = {The pathophysiology of inflammatory bowel disease (IBD) involves the production of diverse lipid mediators, namely eicosanoid, lysophospholipids, and platelet-activating factor, in which phospholipase A(2) (PLA(2)) is the key enzyme. Thus, it has been postulated that control of lipid mediators production by inhibition of PLA(2) would be useful for the treatment of IBD. This hypothesis has been tested in the present study by examining the therapeutic effect of a novel natural probitic Bacillus subtilis PB6 (ATCC- PTA 6737). B. subtilis PB6 is found to secrete surfactins (cyclin lipopeptides) which have anti-bacterial potential. These surfactins inhibit PLA(2), a rate-limiting enzyme involved in the arachidonic acid associated inflammatory pathway and could downregulate the inflammatory response by regulating the eicosanoid and cytokine pathways. With this concept, an experimental animal trial has been conducted in a rat model of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The oral administration of PB6 suppresses the colitis as measured by mortality rate, changes in the weight gain, colon morphology and the levels of plasma cytokines. The animals treated orally with PB6 at 1.5 x 10(8) CFU/kg thrice daily from day 4 to 10 significantly improve gross pathology of the colon and regain the colon weight to normal (p{\textlangle}0.05), compared to TNBS-induced positive control. The plasma levels of pro-inflammatory cytokines (TNR-alpha, IL-1 beta, IL-6 and IFN-gamma) are also significantly lowered (p{\textlangle}0.05) and anti-inflammatory cytokine (IL-10 and TGF-beta) significantly (p{\textlangle}0.05) increased after the oral administration of PB6 on day 11. The present study supports the concept that PB6 inhibits PLA(2) by the secreting surfactins. In a clinical investigation it is found to be well tolerated by all the healthy volunteers.},
  author       = {Selvam, R and Maheswari, P and Kavitha, P and Ravichandran, M and Sas, Benedikt and Ramchand, CN},
  issn         = {0301-1208},
  journal      = {INDIAN JOURNAL OF BIOCHEMISTRY \& BIOPHYSIC},
  keyword      = {Bacillus subtilis PB6,Inflammatory bowel disease,TNBS-induced colitis,Wistar rats,Cytokines,ACTIVATED PROTEIN-KINASE,TUMOR-NECROSIS-FACTOR,LACTIC-ACID BACTERIA,INDUCED COLITIS,LACTOBACILLUS STRAINS,CELLS,MURINE,MICE,INHIBITOR,MODEL},
  language     = {eng},
  number       = {1},
  pages        = {79--85},
  title        = {Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease},
  url          = {http://nopr.niscair.res.in/bitstream/123456789/3339/1/IJBB\%2046(1)\%2079-85.pdf},
  volume       = {46},
  year         = {2009},
}

Chicago
Selvam, R, P Maheswari, P Kavitha, M Ravichandran, Benedikt Sas, and CN Ramchand. 2009. “Effect of Bacillus Subtilis PB6, a Natural Probiotic on Colon Mucosal Inflammation and Plasma Cytokines Levels in Inflammatory Bowel Disease.” Indian Journal of Biochemistry & Biophysic 46 (1): 79–85.
APA
Selvam, R., Maheswari, P., Kavitha, P., Ravichandran, M., Sas, B., & Ramchand, C. (2009). Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC, 46(1), 79–85.
Vancouver
1.
Selvam R, Maheswari P, Kavitha P, Ravichandran M, Sas B, Ramchand C. Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC. 2009;46(1):79–85.
MLA
Selvam, R, P Maheswari, P Kavitha, et al. “Effect of Bacillus Subtilis PB6, a Natural Probiotic on Colon Mucosal Inflammation and Plasma Cytokines Levels in Inflammatory Bowel Disease.” INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSIC 46.1 (2009): 79–85. Print.